Systemic Advanced Therapies Show Strong Efficacy for Extraintestinal Manifestations in IBD
Systemically directed advanced therapies demonstrated high efficacy for musculoskeletal and dermatologic extraintestinal manifestations (EIMs) of inflammatory bowel disease (IBD), while vedolizumab showed comparatively lower effectiveness, particularly for axial arthritis, according to a systematic review and meta-analysis published in Inflammatory Bowel Diseases.
Key Clinical Summary
-
A systematic review and meta-analysis of 49 studies found that TNF antagonists, JAK inhibitors, and anti-IL therapies were associated with substantial improvement in musculoskeletal and cutaneous extraintestinal manifestations (EIMs) of inflammatory bowel disease (IBD).
-
TNF antagonists improved musculoskeletal EIMs in 61% of patients overall, including 73% with peripheral arthritis and 57% with axial arthritis; JAK inhibitors achieved a 65% improvement rate.
-
Vedolizumab demonstrated lower efficacy for musculoskeletal EIMs, with 42% overall improvement and only 12% improvement in axial arthritis. Evidence for ocular EIMs remained limited.
Inflammatory bowel disease frequently extends beyond the gastrointestinal tract, with extraintestinal manifestations affecting approximately one in five patients with Crohn’s disease (CD) or ulcerative colitis (UC). As biologic and targeted therapies have expanded, investigators examined whether treatments effective for intestinal inflammation also improve disease manifestations involving the joints, skin, and eyes.
Study Findings
The systematic review and meta-analysis, published in Inflammatory Bowel Diseases, evaluated the efficacy of five 5-approved classes of advanced therapies for extraintestinal manifestations of IBD: tumor necrosis factor (TNF) antagonists, Janus kinase (JAK) inhibitors, anti-integrins, anti-interleukin (anti-IL) therapies, and sphingosine-1-phosphate (S1P) receptor modulators.
Investigators identified 49 eligible studies, including 6 randomized clinical trials, one pooled clinical trial analysis, and 42 observational studies. The analysis focused on treatment responses in musculoskeletal, dermatologic, and ocular manifestations.
For musculoskeletal EIMs, TNF antagonists demonstrated clinical improvement in 61% of patients overall. Response rates differed by disease subtype, reaching 73% for peripheral arthritis compared with 57% for axial arthritis. JAK inhibitors produced similar efficacy, with an overall improvement rate of 65%.
Vedolizumab showed lower effectiveness for musculoskeletal manifestations, with an overall improvement rate of 42%. Outcomes were particularly limited for axial arthritis, where only 12% of patients experienced clinical improvement.
Cutaneous EIMs responded favorably to systemic therapies. TNF antagonists achieved improvement in 89% of patients, while anti-IL therapies demonstrated a 91% response rate. Evidence for ocular manifestations was substantially more limited, with the review identifying a "paucity of data on ocular EIMs."
Clinical Implications
The findings suggest that treatment selection for patients with IBD should account not only for control of intestinal inflammation but also for the presence and type of extraintestinal manifestations. Systemically directed therapies—including TNF antagonists, JAK inhibitors, and anti-IL agents—demonstrated consistent efficacy across musculoskeletal and dermatologic EIMs, supporting their use when disease extends beyond the gastrointestinal tract.
In contrast, the comparatively lower response rates observed with vedolizumab, particularly for axial arthritis, highlight potential differences in therapeutic effectiveness across drug classes. Clinicians managing patients with significant joint involvement may wish to consider these data when selecting advanced therapies, especially when axial musculoskeletal symptoms are present.
The review also underscores an important evidence gap for ocular manifestations of IBD, where limited published data prevent firm conclusions regarding the comparative effectiveness of currently available advanced therapies.
Expert Commentary
The study authors concluded that "systemically directed ATs (TNF-antagonists, JAK inhibitors, anti-ILs) demonstrated strong efficacy for musculoskeletal or cutaneous EIMs," while vedolizumab achieved lower response rates, particularly for axial arthritis. According to the investigators, these findings may help guide therapeutic decision-making for patients with inflammatory bowel disease whose manifestations extend beyond the gastrointestinal tract.
Reference
Sachdeva K, Manik D, ChhibbaT, Ananthakrishnan A. Advanced therapies for extraintestinal manifestations of IBD: a systematic review and meta-analysis. Inflammatory Bowel Diseases. 2026;, izag075. https://doi.org/10.1093/ibd/izag075
